Low molecular weight heparins (LWMH) are the preferred initial treatment for many
thromboembolic disorders but are renally excreted and relatively contraindicated in patients …

Anaemia is an important component of diabetic nephropathy but only recently has it
attracted the attention of diabetologists and nephrologists. In diabetic patients, anaemia is …

Background. Treatment modalities of renal replacement therapy differ in their diffusive and
convective mass transfer characteristics. It was the goal of this study to clarify whether an …

The need for anticoagulation in dialysis patients is common and the incidence of venous
thromboembolism (VTE) and atrial fibrillation in this population is high. While direct data are …

Generation of factor XII, thrombin antithrombin complexes, prothrombin fragment 1+ 2 and
thrombus precursor protein has been monitored in 16 subjects during haemodialysis …

Background: Low-molecular-weight heparin (LMWH) is supposed to be advantageous
compared to unfractionated heparin for chronic hemodialysis (HD) with respect to lipid and …

No wholly satisfactory drug or system has yet been devised for preventing thrombosis in
extracorporeal blood circuits needed for renal replacement treatments. Heparin is still …

There is no consensus on the dose of low-molecular-weight (LMW) heparin for
thromboprophylaxis in pregnant women at increased risk of thrombosis. Based upon …

Elimination of uremic solutes with molecular weights up to 60 kD, without significant loss of
albumin is an important therapeutic goal to optimize outcomes in chronic hemodialysis …

End-stage renal disease (ESRD) can result from a wide variety of different kidney diseases.
Currently, 90% of patients reaching CKD have chronic diabetes mellitus, glomerulonephritis …